Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Observational Study to Assess the Long-term Safety and Immunogenicity of Olipudase Alfa Therapy During Routine Clinical Care in Pediatric Patients Less Than 2 Years of Age With Acid Sphingomyelinase Deficiency

NCT06192576 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT06192576
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06192576 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Observational Study to Assess the Long-term Safety and Immunogenicity of Olipudase Alfa Therapy During Routine Clinical Care in Pediatric Patients Less Than 2 Years of Age With Acid Sphingomyelinase Deficiency
Lead sponsor
Sanofi
Phase
Observational
Overall status
Recruiting
Start date
April 16, 2024
Completion date
January 15, 2029
Enrollment
10 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

acid sphingomyelinase deficiency, niemann-pick diseases